The yin and yang functions of extracellular ATP and adenosine in tumor immunity

Li-li Feng¹, Yi-qing Cai¹, Ming-chen Zhu⁵, Li-jie Xing¹ and Xin Wang¹,²,³,⁴*

Abstract
Extracellular adenosine triphosphate (eATP) and its main metabolite adenosine (ADO) constitute an intrinsic part of immunological network in tumor immunity. The concentrations of eATP and ADO in tumor microenvironment (TME) are controlled by ectonucleotidases, such as CD39 and CD73, the major ecto-enzymes expressed on immune cells, endothelial cells and cancer cells. Once accumulated in TME, eATP boosts antitumor immune responses, while ADO attenuates immunity against tumors. eATP and ADO, like yin and yang, represent two opposite aspects from immune-activating to immune-suppressive signals. Here we reviewed the functions of eATP and ADO in tumor immunity and attempt to block eATP hydrolysis, ADO formation and their contradictory effects in tumor models, allowing the induction of effective anti-tumor immune responses in TME. These attempts documented that therapeutic approaches targeting eATP/ADO metabolism and function may be effective methods in cancer therapy.

Keywords: Extracellular adenosine triphosphate, Adenosine, CD39, CD73, Tumor immunity

Background
Adenosine triphosphate, also known as ATP, is actively released to the extracellular environment in response to tissue damage and cellular stress. The concentration of cellular ATP is 3 to 10 mM. However, the concentration of extracellular ATP (eATP) is only about 10 nM [1]. The concentration gradient is maintained by ecto-nucleotidases, such as CD39 and CD73, which hydrolyze released ATP rapidly to adenosine diphosphate (ADP), adenosine monophosphate (AMP), and then adenosine (ADO) [2]. CD39/ecto-nucleoside triphosphate diphosphohydrolase-1 (ENTPDase1) is the dominant ecto-nucleotidase broadly expressed on immune cells, endothelial cells (ECs) and tumor cells, which drives the sequential hydrolysis of ATP and ADP to AMP [3]. The formation of AMP to ADO is accomplished primarily through ecto-5-nucleotidase (CD73), a glycosyl phosphatidylinositol-linked membrane protein, also expressed on various immune cells, ECs and tumor cells [4].

Hypoxia, acute and chronic inflammation, platelet aggregation and anticancer therapies induce tumor cells death and metabolic changes, leading to the increased concentrations of eATP and ADO in tumor microenvironment (TME) [5]. The accumulation of extracellular nucleotides and nucleosides is negligible in healthy tissues, except in highly secluded compartments, such as synaptic clefts and the interstitium of exercising muscle [6, 7]. However, the increase of eATP and ADO comprises important components in TME, which is a complex system consisting of host derived microvasculature, stroma, endothelial cells, pericytes, fibroblasts, smooth muscle cells and immune cells, characterized further by hypoxia, acidosis and high interstitial fluid pressure [8]. The components in TME communicate with each other, and also with cancer cells, regulating cellular processes which can inhibit or promote tumor growth [9]. They participate in tumor genesis and development through various mechanisms. In TME, eATP boosts antitumor immune responses while ADO attenuates immune response against tumors [10, 11]. eATP and ADO, like...
yin and yang, represent two opposite aspects from immune-activating to immune-suppressive signals in tumor immunity.

CD39, CD73, ATP and ADO have been proposed as therapeutic targets in oncology. Therapeutic strategies have been developed to modulate eATP/ADO metabolism and related anti-cancer immune responses. In this review, we focused on the effects and related mechanisms of eATP and ADO in tumor immunity, and then discussed the possibility of targeting purinergic signaling in cancer therapy.

eATP and ADO receptors in TME

Increased eATP in TME exhibits multiple functions in combination with ADO receptors. There are two P2 receptor families: P2X receptors (P2X1-7) which are ATP-gated ion channels and P2Y receptors which are G protein-coupled receptors (P2Y1, P2Y1, 2, 4, 6, 11–14) [12]. Different P2 receptors have different affinity/specificity according to expressed cells, whereby modulating different cellular functions [13].

P2X1, 4, 5 receptors were found to express on multiple tumor cells and host cells, especially in hematological malignancies, including acute lymphocytic leukemia, acute myeloid leukemia and multiple myeloma [14, 15]. Their activation mainly associated with the intracellular Ca$^{2+}$ and Na$^+$ increase. In hematological malignancies and solid tumors, the activation of P2X7R not only increased intracellular Ca$^{2+}$ and Na$^+$ but also decreased intracellular K$^+$ [14]. The roles of ATP were depending upon the concentration of eATP in TME. Low eATP levels were anticipated to promote cancer proliferation and immunosuppression, while high levels would promote antitumor immunity [14].

Different P2YR subtypes are activated by different nucleotides. ATP is the preferred ligand only for P2Y11R. For other P2YRs, pyrimidine nucleotides and ADP are more potent agonists. The expression of P2Y11R was found on Huh7 and HepG2 hepatocellular carcinoma cells, hematopoietic stem cells (HSCs) and dendritic cells (DCs) [14]. P2YRs are G protein-coupled and usually activate phospholipase C-IP3 pathway which modulates endoplasmic reticulum Ca$^{2+}$ release. Three Gi/o-coupled subtypes (P2Y12, P2Y13 and P2Y14) mainly inhibit adenylyl cyclase to regulate cyclic AMP (cAMP)/protein kinase A (PKA) pathway [16, 17].

eATP in tumor immunity

Contemporary perspectives highlight the roles of TME in tumor growth and therapy. Increasing evidence indicated that targeting TME could complement traditional treatment and improve therapeutic outcomes for malignancies. As a major component, eATP in TME is at a high concentration [18, 19]. The activation of P2X7R mediates high concentrated ATP-induced tumor cells death directly [20]. Besides the direct inhibition of tumor growth, eATP communicates with other immune cells in TME to regulate tumor growth (Fig. 1).

eATP and monocytes (Mo)/macrophages (Mo)

Tumor-associated macrophages (TAMs) are key members in TME. Macrophages (Mo) play different roles in tumor growth depending on their polarization to classically-activated macrophages (M1s, release tumor necrosis factor-alpha (TNF-α)) or alternatively-activated macrophages (M2s, release IL-10) [21]. M1s conduct the pro-inflammation and anti-tumor effects, while M2s mainly exhibit anti-inflammation and tumor promoting effects. M2s play important roles in cancer cell survival, proliferation, stemness and invasiveness, along with angiogenesis and immunosuppression [22]. M1 cells have a low expression of ecto-nucleotidases and rate of ATP hydrolysis as compared to M2 cells [23]. The effects of eATP on Mo/Mø also depend on the levels of eATP and receptor subtypes. eATP at a high concentration functions as a danger signal activating P2X7R and leading to the activation of the NLRP3 proinflammatory inflammasome pathway in M1s [24]. Low levels of eATP and other nucleotides, such as ADP and UTP, activate the G-protein-coupled P2YRs to mediate chemotaxis of myeloid cells to damaged tissues [25]. eATP at micromolar concentration also functions as a chemotaxtactant for Mo migration to tumor [26]. In addition, eATP has a considerable impact on cytokine production from Mo/Mø. eATP at millimolar concentration stimulates production of IL-1α, IL-1β, IL-6, IL-18, chemokine (C–C motif) ligand (CCL)-2 and TNF-α [27] via P2X7 receptor expressed on Mo/Mø [28, 29]. Recently, accumulated evidences supported the roles of multiple P2XR and P2YR subtypes in Mo/Mø, including P2X1R, P2X4R, P2X5R, P2X7R, P2Y2R, P2Y4R, P2Y6R, P2Y11R, P2Y13R and P2Y14R, which potentially conduct cytokine release and phagocytosis respectively [30]. Macrophage differentiation in the presence of ADO results in an M2-like phenotype [24]. The effects of extracellular nucleotides on M2 cells are mainly mediated by ADO (described below).

eATP and DCs

DCs are the most important antigen presenting cells (APCs) playing a pivotal role in tumor immunity. eATP not only affects DCs maturation and migration, but also contributes to the antigen endocytosis, cytokine production and ectonucleotidase expression. eATP induces up-regulation of activation and maturation markers (i.e. CD80, CD83, CD86, CD54, human leukocyte antigen DR (HLA-DR) and major histocompatibility complex
(MHC)-II) in human peripheral blood mononuclear cell (PBMC)-derived immature DCs, possibly by stimulation of P2Y11R and P2X7R [31]. Maturating DCs then migrate from peripheral tissues to T cells areas to deliver antigens and immunomodulatory messages [32]. Activation of P2Y12R increases antigen endocytosis of DCs with subsequent T cells activation [33]. eATP also has effects on cytokine production from DCs. It has been reported that eATP triggers NOD-like receptor family NLRP3-dependent caspase-1 activation complex ("inflammasome"), allowing the secretion of IL-1β through activation of P2X7R on DCs [34]. eATP is also found to promote IL-23 and vascular endothelial growth factor (VEGF) production from DCs in vitro, which is potentially mediated by P2Y11R [31, 35]. Higher IL-23 is essential for Th17 polarization and magnifying Th17-promoting activity of DCs [31]. However, when there is low level of eATP (uM), TNF-α, IL-12 and IL-1 from DCs are completely abrogated [36]. It was recently reported that P2X7R was able to influence the expression of CD39 and CD73 on DCs. P2X7 pharmacological blockade leads to a reduction of tumor volume and an increase of extracellular ATP with conventional DCs down-modulate CD39 and CD73 [37]. In acute myeloid leukemia patients and mice, it was found that ATP release from chemotherapy-treated dying cells increased number of IDO1+CD39+ DCs [38].

**eATP and T cells**

Recent studies have shown that eATP regulates T cell activation, cytokine production and lymphocyte metabolism [39, 40]. P2X receptor subtypes are found to involve in T-cell activation which requires a sustained elevation of intracellular Ca^2+ levels. All P2XRs, with the exception of P2X5, can facilitate entry of Ca^2+ in response to stimulation by eATP, suggesting that P2X receptors regulate...
T-cell activation by increasing intracellular Ca$^{2+}$ [41]. P2XRs activation by ATP also protracts the T cell receptor (TCR)-initiated activity of MAPKs and secretion of IL-2 [42]. In contrary, removal of eATP or inhibition, mutation or silencing of P2X1, P2X4 or P2X7 receptors inhibits Ca$^{2+}$ entry, nuclear factors of activated T cells (NFAT) activation and T-cell activation [41, 43–45]. For T cells, P2X7R is found to distribute uniformly across the cell surface and can be activated by high concentration of eATP, occurring in damaged tissue and under cellular stress. This feature of P2X7R facilitates T cells to distinguish damaged tissues, especially in TME [46]. P2X7R also plays important roles in eATP (100–300 μM) stimulated mitogen-induced CD4$^+$ and CD8$^+$ T cells proliferation. eATP also acts as a potent chemoattractant for T cells through P2YRs signaling [36]. Extracellular ATP produced by damaged tissue or exported by activated cells, is found not only triggers immune activation but plays an additional critical role by promoting metabolic fitness and survival of the most durable and functionally relevant memory CD8$^+$ T cell populations through the activation of P2X7R [40].

Extracellular ATP and its receptor P2X7 also exert a pivotal influence on cancer growth through modulating lymphocytes infiltration in TME, including CD4$^+$, CD8$^+$ lymphocytes and regulatory T cells (Tregs). Elena De Marchi et al. [37] reported that tumors growing in P2X7 null mice showed a decrease in CD8$^+$ cells and an increased number of Tregs, overexpressing the fitness markers OX40, PD-1, and CD73. However, systemic administration of the P2X7 blocker A740003 in wild-type mice showed increased CD4$^+$ effector cells and decreased their expression of CD39 and CD73. These data illustrated that P2X7 receptor was a key determinant of TME composition.

In addition, eATP is a modulator for T cells function transformation. Antagonists of P2XRs can promote the cell-autonomous conversion of naïve CD4$^+$ T cells to Tregs after TCR stimulation [41]. The activation of P2X7R not only reduces Treg cells numbers, but also inhibits Treg cells generation, suppressive function and stability [38]. eATP released by commensal bacteria was also found to drive the differentiation of intestinal CD4$^+$ T cells to Th17 cells [1]. Another study confirmed that the activation of P2X7R on follicular helper T (Tfh) cells weakened germinal center reactions and immune globulin (Ig) A secretion, and resulted in increased serum IgM [46].

**eATP and eosinophils, neutrophils and B cells**

The participation of eosinophils in innate Th2-type immune responses is mediated by eATP [47]. eATP also promotes eosinophils functions through P2Y2R, including adhesion and superoxide generation [48]. Human eosinophils release eosinophil cationic protein (ECP), IL-6 and IL-8 by P2Y2 receptor stimulation, while P2X1, P2X7, and P2Y6 receptors might also be implicated in the release of IL-8 [47, 49]. In hypoxia, neutrophils contribute to production of eATP. In return, the activation of P2Y2R by eATP promotes neutrophils migration to chemottractants [50]. Neutrophils also express functional P2X7R, involving in the secretion of IL-1β and IL-18 [51]. In addition, activation of P2Y11R helps neutrophils to retain the immune functions and prolong the longevity under stress [30]. For B cells, the activation of P2X7R mainly mediates B-cell survival and proliferation [52].

**ADO and ADO receptors in TME**

Similar to eATP, the concentration of ADO is at a low level in extracellular media (lower than 1 μM). However, its concentration notably increases under many metabolically stressful conditions, especially in TME (over 100 μM) [19]. The bulk of extracellular ADO is generated from eATP thanks to sequential hydrolysis of CD39 and CD73 [17]. ADO binds to its receptors (A1, A2A, A2B, and A3) presented on immune cells and tumor cells, regulating tumor progression and multiple immune responses, including tumor immunity [53]. A2A and A2B receptors (A2AR and A2BR) are Gs-coupled receptors that increase intracellular cAMP and PKA levels, playing dominant roles in ADO-induced immunosuppression in a cAMP-dependent manner [54]. A1 and A3 receptors (A1R and A3R) are Gi/o-coupled receptors that decrease intracellular cAMP, thereby favoring cell activation but also inducing activation of phosphatidylinositol 3-kinase (PI3K), extracellular-signal-regulated kinase (ERK)1/2 and protein kinase C (PKC) [55, 56]. Receptors with high-affinity (A1R, A2AR and A3R) are involved when ADO is at low concentrations, whereas at high concentrations, the low-affinity A2BR is involved, like those observed in TME [57].

ADO affects tumor progression directly through binding on its specific receptors expressed on cancer cells. Extracellular ADO in TME chronically activates A2BR expressed on cancer cells to suppress Ras-related protein (Rap)-1B prenylation and signaling, resulting in cell–cell contact reduction and cell scattering promotion. The major effect of A3R activation is to promote angiogenesis [58].

**Extracellular ADO in tumor immunity**

Extracellular ADO in TME is also an important factor controlling antitumor immunity, conditioning both innate and adaptive immune responses (Fig. 2).
Fig. 2 Extracellular adenosine (ADO) at a high concentration (over 100 μM) conducted immune-suppressive functions through activation of different ADO receptors on immune cells in tumor microenvironment (TME). For T cells in TME, ADO not only decreases anti-tumor function of CD8+ T cells, Th1 cells and Th2 cells but also enhances the function of regulatory T cells (Treg), Th17 cells and Tc17 cells. ADO also affects B cells, dendritic cells (DCs), mast cells (MCs), natural killer (NK) cells and macrophages (Mø) functions in anti-tumor immunity.
ADO and T cells

ADO is emerging as an important negative regulator of T-cell function for inhibition of mobility, migration and adhesion [59–61]. The inhibition role of ADO in anti-tumor T cells is mediated by A2AR and A2BR. Pharmacological blockade of A2AR not only enhances CD8+ T cells anti-tumor response but also reduces the population of Tregs [62]. A2AR antagonist or silence by siRNA could improve the inhibition of tumor growth, destruction of metastases and prevention of neovascularization by anti-tumor T cells [63]. For Treg cells, ADO not only promotes CD4+ T cells differentiation to Tregs [17], but also facilitates Treg cells suppressive function through A2AR activation [64]. Antagonists of A1R and A2BR also suppress the expression of Foxp3 and the production of IL-10 from Tregs [65]. Moreover, human Tregs over-express CD39 and CD73, which are beneficial to ADO production. ADO then binds to A2AR on effector T cells and suppresses their functions [66]. Meanwhile, Treg cells express low levels of adenosine deaminase (ADA), the enzyme responsible for ADO breakdown, and CD26, a surface-bound glycoprotein associated to ADA, which is helpful to maintain the high concentration of ADO in TME [67]. A2AR activation on T cells under hypoxia could also suppress the development of Th1 and Th2 immune responses, both in vitro and in vivo [68]. A2BR is found to play important roles in the effects of ADO on Th17 cells. A2BR activation promotes Th17 response through DCs activation and differentiation from bone marrow cells to a CD11c+Gr-1+ DC subset [69, 70]. Another subset of T cells, named Type 1 cytotoxic CD8+ T (Tc1) cells, is latterly recognized as IL-17-producing CD8+ T (Tc17) cells. It is demonstrated that Tc17 cells stably sustain the stem-cell-like program and reject the differentiation to Tc1-like cells with the help of ADO, consequently activating A2AR, which turns Tc17 cells to long-lived memory T cells to allow the immunosuppressive properties in tumor progression [71].

ADO and B cells

Abundant expression of CD39 and CD73 on human B cells facilitates an efficient accumulation of ATP-generated ADO, thus contributing to T cell-B cell interactions [72]. B cells have been found to express A1R, A2AR and A3R, but not A2BR. Agonists and antagonists studies were conducted to determine which ADO receptor was involved in B cells suppressive signals delivery. A selective A3R antagonist was found to stimulate proliferation of resting B-cells while a A3R agonist inhibited their proliferation, indicating that ADO produced by resting B cells exerted autocrine action [73]. Activated human B cells could also down-regulate proliferation of autologous CD4+ and CD8+ T cells through ADO [73]. Recently, a new paradigm of regulatory B cells (Bregs) was introduced [74] and they were thought to be able to control CD4+ T-cell responses [75]. Functional regulation of Bregs is manipulated by different ADO receptors respectively. A1R and A2AR contribute to the proliferation and functions of CD39high B cells while A2BR activation is critically required for IL-10 production [76].

ADO and DCs

ADO, an important modulator of DCs functions, has significant effects on DCs activation, maturation, as well as cytokine production. A1R, A2AR and A3R are expressed by human monocyte-derived DCs. For immature DCs, ADO not only induces Ca2+ transients resulting in actin polymerization and chemotaxis, but also increases co-stimulatory molecules expression [30]. For mature DCs, ADO increases cAMP and IL-10 secretion while inhibits IL-12 and TNF-α production [77]. ADO is also found to activate human monocyte-derived DCs through A2AR [78] and murine bone marrow-derived dendritic cells (BMDCs) through A2BR [79]. However, unlike normal myeloid DCs, ADO-differentiated DCs have impaired allostimulatory activity and express high levels of angiogenic, pro-inflammatory, immune suppressor and tolerogenic factors [80]. ADO-conditioned DCs also have potential to regulate polarization of some T-cell subtypes. In vitro, ADO-conditioned DCs reduce the capacity of Th1 polarization from CD4+ T cells in a cAMP-dependent manner [81]. DCs from A2BR agonist-treated mice showed a significantly increased ability to activate γδ T cells and Th17 autoreactive T cells [69]. Moreover, ADO deaminase knockout animal models showed that elevated levels of extracellular ADO were highly associated with DCs with a pro-angiogenic phenotype [82]. Therefore, a defective function of DCs under the activation of ADO-A2AR/A2BR axis in TME allows tumor to escape immune surveillance.

ADO and mast cells (MCs)

The amount of tumor-infiltrating MCs has a close relationship with tumor aggressiveness and dissemination [83]. A2AR, A2BR, and A3R are found to be expressed on MCs. A2BR activation limits cells degranulation [84]. The combination of A2AR and A2BR activation is required for the inhibition of cytokine synthesis both in vitro and in vivo [85, 86]. MCs isolated from wild type (WT), not A2BR knocked out (KO) mice, release IL-13 and VEGF in response to extracellular ADO, suggesting the role of A2BR in angiogenesis [87]. However, A3R activation has been proven to mediate MCs activation through ERK1/2 phosphorylation in TME [88].
ADO and natural killer (NK) cells
For NK cells, which are a type of innate immune cells, increased levels of adenosine in tumor environment inhibit the lytic activity of NK cells via binding to A2A receptors [89]. A2AR deletion increases proportions of mature NK cells at homeostasis, following reconstitution in TME. Targeting A2AR specifically on NK cells delays tumor genesis, suggesting A2AR-mediated signaling as an intrinsic negative regulator for NK cells maturation and antitumor immune responses [90].

ADO and Mø
Increased ADO concentration could also induce Mø recruitment in TME. Mø plays various roles in an ADO-dependent manner [91]. A1R, A2AR, A2BR and A3R are all expressed on Mø cells. But the effects of ADO on Mø cells are predominantly mediated by A2AR. As described before, Mø cells played opposite roles depending on their polarization to M1s or M2s. A2AR activation leads to the increase of cAMP and the activation of CCAAT-enhancer-binding protein-β, thereby increase M2 macrophage polarization [92]. ADO also inhibits classical Mø activation [93]. For cytokine production, ADO not only inhibits TNF-α, IL-6, and IL-12 release but also enhances IL-10 and VEGF production from Mø [94, 95].

Targeting purinergic signaling as potential target in cancer therapy
Given the yin and yang function of eATP and ADO in tumor immunity, targeting their signaling pathways and their metabolism has attracted more and more attention in tumor therapy.

P2 receptors as tumor therapeutic targets
Among P2Rs, P2X7R is the most potential candidate in anticancer therapy [96]. P2X7R was reported to be expressed in multiple malignant tumors, including neuroblastoma [97], melanoma [98], prostate cancer [99], lung cancer [100] and breast cancer [101]. P2X7R antagonists could inhibit tumor growth and migration [96]. With pretreatment of P2X7R antagonists (including A-740003, A438079 and KN62), ATP-evoked tumor growth (ATP < 1.0 mM) was inhibited via PI3K/AKT and AMP-activated protein kinase (AMPK)/mTOR pathways [97, 102, 103]. Another P2X7R antagonist, named AZ10606120, was found to execute growth-inhibitory effect in neuroblastoma through PI3K/GSK3β/hypoxia-inducible factor 1-alpha (HIF-1α) pathway downregulation [104]. Moreover, P2X7R antagonists could affect inflammatory cytokines secretion. A740003 not only inhibited IL-10, IL-6 and monocyte chemoattractant protein-1 (MCP-1) release from macrophage [77], but also reduced cancer antigen presentation and cancer cell proliferation [105]. By down-regulated CXCL1, MCP-1 and VEGF secretion, P2X7R antagonist (such as BBG and AZ10606120) contributed to inhibition of endothelial progenitor cells (EPCs) as well as vascular density and tumor neovascularization [106, 107]. Another form of P2X7R, which is not able to form a functional pore and termed as non-pore functional P2X7R (nfP2X7R), has been described recently [101]. Researchers found that antibodies against amino acid sequence specifically for nfP2X7R also had a key role in cancer growth [108], which documented that antagonists specifically for nfP2X7R may be potential effective therapeutic agents in cancer therapy.

P2Y12R is another important member in P2R family. Under ATP and ADP stimulation, P2Y1R initiates platelet activation followed by the ADP-P2Y12R-mediated amplification [109]. P2Y12R represents a potential target in cancer therapy due to its involvement in platelet-cancer cell crosstalk. Thus, P2Y12R antagonists, including clopidogrel, ticagrelor and prasugrel, might represent potential anti-cancer agents [110].

ADO receptors as tumor therapeutic targets
Strategies targeting ADO receptors appear to be attracting approaches to block ADO immunosuppressive effects and boost anti-tumor immunity. In a sarcoma model and the poorly immunogenic LL-LCMV tumor model, pharmacologic blockade of A2AR enhanced T cell mediated tumor regression [63]. The ability of A2AR blockade to suppress metastasis has also been validated [111]. A2AR blockade and programmed death-1 (PD-1)/cytotoxic T-lymphocyte–associate antigen 4 (CTLA-4) monoclonal antibody (mAb) combined therapy also illustrated impressive effects in a variety of syngeneic tumor models [112]. Most recently, it was reported that A2AR blockade had high potential to enhance chimeric antigen receptor (CAR)-T cells efficacy in some cancers [113]. There are some agents targeting the A2AR for cancer immunotherapy in Phase 1 trials, including CPI-444 (Corvus), PBF-509 (Novartis/Pablobiofarma), MK-3814 (Merck), AZD4635 (AstraZeneca/Heptares). Each of these trials includes cohorts receiving monotherapy as well as A2AR blockade in combination with blockade of the PD-1/PD-L1 pathway [114]. A2BR is a low-affinity receptor, but its expression is highly transcriptionally regulated by HIF-1α in TME. When tumor A2BR was blocked, the decreased metastasis was observed in multiple tumors [80, 115]. A2BR inhibitor also showed significant anti-tumor effects when combined with anti-PD-1 and anti-CTLA-4 mAbs [115].
**CD39 and CD73 as tumor therapeutic targets**

Considering critical roles of CD39/CD73 in ATP/ADO metabolism, attempts to block CD39/CD73 activity have been tried in tumor therapy. When compared to CD39 over-expressing mice, colorectal cancer cells and melanoma cells in CD39 deficient models showed significantly slower hepatic and pulmonary metastases [116]. Inhibition of CD39 activity by polyoxometalate1 (POM-1) abrogated production of IL-10 from TAMs, functionally diminished immunosuppressive functions [117]. Even for sarcoma, which lacked effective therapeutic intervention, CD39 inhibitory mAb was proven to have prolonged survival in a lethal metastatic patient-derived sarcoma model [118]. Some pharmaceutical companies are currently developing anti-human CD39 mAb, such as Innate Pharma in France. CD73 blockade was also found to have favorable antitumor effects via modulating immune response in TME. CD73-deficient mice were demonstrated to sustain activated antitumor immunity, influencing neo-vascularization, tumor growth and metastasis [119, 120]. CD73 inactivation was proved to inhibit progression of breast cancer and head and neck squamous cell carcinoma [121, 122]. Likewise, anti-CD73 blocking antibody was also documented to impact spontaneous lung metastasis and decrease circulation capability of cancer cells [4]. Anti-CD39 and anti-CD73 monoclonal antibodies and their combination with immune checkpoint inhibitors and chemotherapies in cancer also showed promoted antitumor immunity [123]. CD73 inhibitors alone and in combination with other drugs in cancer patients are currently under clinical trials (such as NCT03454451, NCT02503774 and NCT03381274 registered at clinicaltrials.gov).

**Conclusions and future perspectives**

Purinergic signaling has emerged as a novel mechanism to modulate anticancer immunity. The accumulations of eATP and ADO in TME play yin and yang functions in tumor immunity through their specific receptors. The metabolism from eATP to ADO is accomplished mainly through CD39 and CD73, which expressed on immune cells, endothelial cells as well as cancer cells in TME. Drugs and biological approaches blocking eATP hydrolysis, ADO formation and their effects have the potential to overcome tumor immunosuppression, allowing the induction of effective anti-tumor immune responses. This strategy could also be a new option to improve the efficacy of cytotoxic agents and checkpoint blockade inhibitors. However, given the multifaceted effects of eATP and ADO in TME, where tumor cells, host immune cells and stromal cells communicate with each other through complicated mechanisms, how to select the most suitable therapy target is still a challenge to be overcome.

**Abbreviations**

ADO: Adenosine; ADP: Adenosine diphosphate; AMP: Adenosine monophosphate; AMPK: AMP-activated protein kinase; APCs: Antigen presenting cells; ATP: Adenosine triphosphate; BMDCs: Bone marrow-derived dendritic cells; Bregs: Regulatory B cells; cAMP: Cyclic adenosine monophosphate; CAR: Chimeric antigen receptor; CCL: Chemokine (C–C motif) ligand; CTLA-4: Cytotoxic T-lymphocyte–associated antigen 4; DCs: Dendritic cells; eATP: Extracellular adenosine triphosphate; ECs: Endothelial cells; EPCs: Endothelial progenitor cells; ERK: Extracellular-signal-regulated kinase; HIF-1α: Hypoxia-inducible factor 1-alpha; HLA-DR: Human leukocyte antigen DR; HSC: Hematopoietic stem cells; Ig: Immune globulin; IL: Interleukin; IFN: Interferon; ITAM: Immunoreceptor tyrosine-based activation motif; KO: Knocked out; mAb: Monoclonal antibody; MCP-1: Monocyte chemoattractant protein-1; MCs: Mast cells; MHC: Major histocompatibility complex; Mo: Monocytes; Macrophages; NFAT: Nuclear factors of activated T cells; nTregs: Natural regulatory T cells; P2X: P2X receptors; P2YR: P2Y receptors; POM-1: Polyoxometalate1; P2X7R: Non-pore functional P2X7R; P65: Nuclear factor kappa B subunit; PI3K: Phosphatidylinositol 3-kinase; PIK3R1: Phosphatidylinositol 3-kinase regulatory subunit 1; PI3K: Phosphatidylinositol 3-kinase; PKC: Protein kinase C; POM-1: Polyoxometalate1; P2X7R: P2X7 receptor; P2YR: P2Y receptors; Rap: Ras-related protein; TAMs: Tumor-associated macrophages; TCR: T cell receptor; Tfh: Follicular helper T cell; TME: Tumor microenvironment; TNFα: Tumor necrosis factor-alpha; Tregs: Regulatory T cells; VEGF: Vascular endothelial growth factor; WT: Wild type.

**Acknowledgements**

Not applicable.

**Authors’ contributions**

XW designed the review. LLF and YQC drafted the manuscript. MCZ and LJX helped modify the manuscript. All authors read and approved the final manuscript.

**Funding**

This study was supported by Grants from National Natural Science Foundation (No. 81500123, 81270598, 81473486 and No. 81770210); Key Research and Development Projects of Shandong Province (No. 2017GG06005 and No. 2018CXGC1213); Technology Development Projects of Shandong Province (No. 2017GSSF18189); Promotive Research Fund for Excellent Young and Middle-aged Scientists of Shandong Province (No. BS2013YY003); Natural Science Foundations of Shandong Province (No. ZR2016HP12); Taishan Scholar Program of Shandong Province; Shandong Provincial Engineering Research Center of Lymphoma; Key Laboratory for Kidney Regeneration of Shandong Province; Academic promotion programme of Shandong First Medical University.

**Availability of data and materials**

No datasets were generated or analysed.

**Ethics approval and consent to participate**

Not applicable.

**Consent of publication**

All authors have reviewed the manuscript and agree to publish it in its current form.

**Competing interests**

The authors declare that they have no competing interests.

**Author details**

1. Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan 250021, Shandong, China.
2. School of Medicine, Shandong University, Jinan 250012, Shandong, China.
3. Shandong Provincial Engineering Research Center of Lymphoma, Jinan 250021, Shandong, China.
4. National clinical research center for hematologic diseases, Jinan 250021, Shandong, China.
5. Department of Clinical
References

1. Trautmann A. Extracellular ATP in the immune system: more than just a ‘danger signal’. Sci Signal. 2009;2(56):pt6.
2. Ferrati D, Gambari R, Izzo M, Muller T, Albanesi C, Pastore S, et al. Purinergic signaling in cancer: FASEB J. 2016;30(1):3–12.
3. de Andrade Mello P, Coutinho-Silva R, Savio LEB. Multifaceted effects of extracellular adenosine triphosphate and adenosine in the tumor-host interaction and therapeutic perspectives. Front Immunol. 2017;8:1526.
4. Antonioli L, Yegutkin GG, Pacher P, Blandizzi C, Hasko G. Anti-CD73 in cancer immunotherapy: awakening new opportunities. Trends Cancer. 2016;2(2):95–109.
5. Cai Y, Feng L, Wang X. Targeting the tumor promoting effects of extracellular adenosine in chronic lymphocytic leukemia. Crit Rev Oncol Hematol. 2018;126:24–31.
6. Burnstock G. Physiology and pathophysiology of purinergic neurotransmission. Physiol Rev. 2007;87(2):659–707.
7. Forrester T. A case of serendipity. Purinergic Signal. 2008;4(2):93–100.
8. Spaw M, Anant S, Thomas SM. Stromal contributions to the carcinogenic process. Mol Carcinog. 2017;56(4):1199–213.
9. Gilabert-Onori R, Ryan GM, Leung AWY, Firmino NS, Bennewith KL, Bally MB. Liposomal formulations to modulate the tumour microenvironment and antimtumor immune response. Int J Mol Sci. 2018;19(10):2022.
10. Regateiro FS, Cobbold SP, Waldmann H. CD73 and adenosine generation in the creation of regulatory microenvironiments. Clin Exp Immunol. 2013;171(1):1–7. https://doi.org/10.1111/j.1365-2249.2012.04623.x
11. Li XY, Moesta AK, Xiao C, Nakamura K, Casey M, Zhang H, et al. Targeting CD39 in cancer reveals an extracellular ATP- and inflammasome-driven tumor immunity. Cancer Discov. 2018;19(10):2922.
12. Anant S, Thomas SM. Extracellular ATP and P2 purinergic signalling in the tumour microenvironment. Nat Rev Cancer. 2014;14(1):135–47.
13. Lecciso M, Ocadlikova D, Sangaletti S, Trabanelli S, De Marchi E, Orioli E. Extracellular ATP release from chemotherapy-treated dying leukemia cells elicits an immune suppressive effect by increasing regulatory T cells and tolerogenic dendritic cells. Front Immunol. 2017;8:1918.
14. Zhao R, Liang D, Sun D. Blockade of extracellular ATP effect by oxidized ATP effectively mitigated induced mouse experimental autoimmune uveitis (EAU). PLoS ONE. 2016;11(5).e0155953.
15. Borges da Silva H, Beura LK, Wang H, Hanse EA, Gore R, Scott MC, et al. The purinergic receptor P2RX7 directs metabolic fitness of long-lived memory CD8+ T cells. Nature. 2018;559(7713):264–8.
16. Woehrle T, Yin L, Elkahal A, Sumi Y, Chen Y, Yao Y, et al. Inhibition of pannexin-1 channel activity in the creation of regulatory microenvironments. Oncotarget. 2017;8:39855–908.
17. Raita MR, Puolakainen PA. Tumor-associated macrophages (TAMs) as biomarkers for gastric cancer: a review. Chronic Dis Transl Med. 2018;4(3):156–63.
18. Najafi M, Hashemi Goradel N, Farhood B, Salehi E, Nashtaei MS, et al. Differential macrophage activation alters the expression profile of NTPDase and ecto-5′-nucleotidase. PLoS ONE. 2012;7(2):e31205.
44. Yip L, Voehrte T, Corrinden R, Hirsh M, Chen Y, Inoue Y, et al. Autocrine regulation of T-cell activation by ATP release and P2X7 receptors. FASEB J. 2009;23(6):1685–93.

45. Kataoka A, Tozaki-Saitoh H, Haga Y, Tsuda M, Inoue K. Activation of P2X7 receptors induces CLL3 production in microglial cells through transcription factor NFKB. J Neurochem. 2009;108(1):115–25.

46. Salles EM, Meneses MN, Siqueira R, Borges da Silva H, Amaral EP, Castillo-Mendez SI, et al. P2X7 receptor drives Th1 cell differentiation and controls the follicular helper T cell population to protect against Plasmodium chabaudi malaria. PLoS Pathog. 2017;13(8):e1006595.

47. Kobayashi T, Kozaki H, Hita H. Human eosinophils recognize endogenous danger signal crystalline uric acid and produce proinflammatory cytokines mediated by autocrine ATP. J Immunol. 2010;184(11):6350–8.

48. Kobayashi T, Soma T, Nogakome K, Nakamoto H, Hita H, et al. ATP drives eosinophil effector responses through P2 purinergic receptors. Allergol Int. 2015;64(Suppl.1):S30–6.

49. Idzik M, Panter H, Bremer HC, Sonchino S, Luttmann W, Virchow CJ, et al. Stimulation of P2 purinergic receptors induces the release of eosinophil cationic protein and interleukin-8 from human eosinophils. Br J Pharmacol. 2003;138(7):1244–50.

50. Chen Y, Corrinden R, Inoue Y, Yip L, Hashiguchi N, Zinckernagel A, et al. ATP release guides neutrophil chemotaxis via P2Y2 and A3 receptors. Science. 2006;314(5806):1792–5.

51. Karmakar M, Katsnelson MA, Dubyak GR, Pearlman E, Fang J, Wang L, et al. P2X7 receptor mediates NLRP3 inflammasome-dependent IL-1beta secretion in response to ATP. Nat Commun. 2016;7:10555.

52. Adinolfi E, Melchiorri L, Falconi S, Chiocchia P, Morelli A, Tieghi A, et al. P2X7 receptor expression in evolutive and indolent forms of chronic B lymphocytic leukemia. Blood. 2002;99(2):706–8.

53. Jin D, Fan J, Wang L, Thompson LF, Liu A, Daniel BJ, et al. CD73 on tumor cells impairs antitumor T-cell responses: a novel mechanism of tumor-induced immune suppression. Cancer Res. 2010;70(6):2245–55.

54. Sorrentino R, Pinto A, Morello S. The adenosinergic system in cancer: key therapeutic target. Oncoimmunology. 2013;2(11):e224484.

55. Taylor SS, Iloz R, Zhang J, Kornev AP. Assembly of allosteric macromolecular switches: lessons from PAK. Nat Rev Mol Cell Biol. 2012;13(10):646–58.

56. Tsuchiya A, Nishizaki T. Anticancer effect of adenosine on gastric cancer via diverse signaling pathways. World J Gastroenterol. 2015;21(39):10931–5.

57. Kazemi MH, Raoofi Mohseni S, Hojjat-Farsangi M, Anvari E, Ghalamzani A, et al. The role of activated adenosine receptors in degranulation of human eosinophils. J Leukoc Biol. 2014;96(1):113–22.

58. A2B adenosine receptors. J Leukoc Biol. 2014;96(1):113–22.

59. Adinolfi E, Melchiorri L, Falconi S, Chiocchia P, Morelli A, Tieghi A, et al. P2X7 receptor expression in evolutive and indolent forms of chronic B lymphocytic leukemia. Blood. 2002;99(2):706–8.

60. Kobayashi T, Soma T, Nogakome K, Nakamoto H, Hita H, et al. ATP drives eosinophil effector responses through P2 purinergic receptors. Allergol Int. 2015;64(Suppl.1):S30–6.

61. Taylor SS, Iloz R, Zhang J, Kornev AP. Assembly of allosteric macromolecular switches: lessons from PAK. Nat Rev Mol Cell Biol. 2012;13(10):646–58.

62. Tsuchiya A, Nishizaki T. Anticancer effect of adenosine on gastric cancer via diverse signaling pathways. World J Gastroenterol. 2015;21(39):10931–5.

63. Kazemi MH, Raoofi Mohseni S, Hojjat-Farsangi M, Anvari E, Ghalamzani A, et al. The role of activated adenosine receptors in degranulation of human eosinophils. J Leukoc Biol. 2014;96(1):113–22.

64. A2B adenosine receptors. J Leukoc Biol. 2014;96(1):113–22.

65. A2B adenosine receptors. J Leukoc Biol. 2014;96(1):113–22.

66. Antonioli L, Pacher P, Vaz ES, Hasko G. CD39 and CD73 in immunity and inflammation. Trends Mol Med. 2013;19(6):355–67.

67. Sauer AV, Brigida I, Carriglio N, Hernandez RJ, Scaramuzza S, Clavenna A, et al. Adenosine receptor antagonists: next generation check-point blockade for cancer immunotherapy. Comput Struct Biotechnol J. 2015;13:265–72.

68. Nakatsukasa H, Tsukimoto M, Harada H, Kojima S. Adenosine A2B receptor antagonist suppresses differentiation to regulatory T cells without suppressing activation of T cells. Biochem Biophys Res Comm. 2011;409(1):114–9.

69. Chen M, Liang D, Zuo A, Shao H, Kaplan HJ, Sun D. An A2B adenosine receptor agonist promotes Th17 autoimmune responses in experimental autoimmune uveitis (EAU) via Dendritic Cell Activation. PLoS ONE. 2015;10(7):e0132348.

70. Chiang J, DiLillo DJ, Horikawa M, Kountikov EI, et al. Regulatory T cells suppress contact hypersensitivity reactions through A2B receptor blockade. J Immunol. 2013;188(1):198–205.

71. Vijayamahantesh, Amit A, Kumar S, Dikhit MR, Jha PK, Singh AK, et al. Up regulation of A2B adenosine receptor on monocytes are crucially required for immune pathology in Indian patients exposed to Leishmania donovani. Cytokine. 2016;79:38–44.

72. Bergamaschini, Pietro P, Varani A, Zanin RF, Sevigny J, et al. Adenosine production by human B cells and B cell-mediated suppression of activated T cells. Blood. 2013;121(19):118–188.

73. Yoshizaki A, Miyagaki T, DiLillo DJ, Matsushita M, Kountikov EI, et al. Regulatory B cells control T-cell autoimmunity through IL-21-dependent cognate interactions. Nature. 2012;491(7423):264–8.

74. Suapep-Easton D, Vincent FB, Quah PS, Wei A, Ting SB, Croce CM, et al. The BAFF receptor TACI controls IL-10 production by regulatory B cells and CLL B cells. Leukemia. 2016;30(1):163–72.

75. Figueiredo AB, Serafin MD, Marques-da-Silva EA, Meyer-Fernandes JR, Afonso LC, Leishmania amazonensis impairs DC function by inhibiting CD40 expression via A2A and A2B adenosine receptors. J Leukoc Biol. 2014;96(1):113–22.

76. Sciaraffia E, Riccomi A, Lindstedt R, Gesa V, Cirelli E, Patrizio M, et al. Human monocytes respond to extracellular cAMP through A2A and A2B adenosine receptors. J Immunology. 2013;181(4):1203–15.

77. Bense RD, Sotiriou C, Piccart-Gebhart MJ, Haanen JB, van Vugt MA, de Vries EC, et al. Relevance of tumor-infiltrating immune cell composition and functionality for disease outcome in breast cancer. J Natl Cancer Inst. 2017. https://doi.org/10.1093/jnci/djw192.
Hasko G, Csoka B, Nemeth ZH, Vizi ES, Pacher P. A(2B) adenosine receptors in immunity and inflammation. Trends Immunol. 2009;30(6):626–70.

Gorzalczany Y, Akiva E, Klein O, Merimsky O, Sagi-Eisenberg R. Mast cells are directly activated by contact with cancer cells by a mechanism involving autocrine formation of adenosine and autocrine/paracrine signaling of the adenosine A3 receptor. Cancer Lett. 2017;397:23–32.

Kumar V. Adenosine as an endogenous immunoregulator in cancer pathogenesis: where to go? Purinergic Signal. 2013;9(2):145–65.

Young A, Ngio SF, Gao Y, Patch AM, Barkauskas DS, Messacaudene M, et al. A2AR adenosine signaling suppresses natural killer cell maturation in the tumor microenvironment. Cancer Res. 2018;78(4):1003–16.

Montalban Del Barrio I, Penski C, Schlafsea L, Stein RG, Diessner J, Wockel A, et al. Adenosine-generating ovarian cancer cells attract myeloid cells which differentiate into adenosine-generating tumor associated macrophages—a self-amplifying, CD39- and CD73-dependent mechanism for tumor immune escape. J Immunother Cancer. 2016;4:49.

Csoka B, Selmezczey Z, Koscs B, Nemeth ZH, Pacher P, Murray PJ, et al. Adenosine promotes alternative macrophage activation via A2A and A2B receptors. FAGB J. 2012;26(1):376–86.

Ryzhov S, Zaynagetdinov R, Goldstein AE, Novitskiy SV, Blackburn MR, Cohen HB, Briggs KT, Marino JP, Ravid K, Robson SC, Mosser DM. TLR agonist activation of the adenosine A2A receptor enhances chimeric antigen receptor T cell efficacy. J Clin Invest. 2017;127(9):929–41.

Leone RD, Emens LA. Targeting adenosine for cancer immunotherapy. J Immunother Cancer. 2018;6(1):57.

Mittal D, Sinha D, Barkauskas D, Young A, Kalimutho M, Stannard K, et al. Adenosine A2B receptor expression on cancer cells promotes metastasis. Cancer Res. 2016;76(15):4372–82.

Allard B, Longhi MS, Robson SC, Stagg J. The ectonucleotidases CD39 and CD73: novel checkpoint inhibitor targets. Immunol Rev. 2017;276(1):121–44.

d’Almeida SM, Kauffenstein G, Roy C, Basset L, Papargyris L, Henrion D, et al. Targeting CD73 restores M2b macrophage polarisation, angiogenesis, and macrophage infiltration. PLoS ONE. 2016;11(3):e0151420.

Bowser JL, Blackburn MR, Shipley GL, Molina JG, Dunner K Jr, Broaddus RR. Loss of CD73-mediated actin polymerization promotes endometrial tumor cell death. PLoS ONE. 2013;8(4):e62184.

Yang X, Pei S, Wang H, Jin Y, Yu F, Zhou B, et al. Tiamulin inhibits breast cancer growth and pulmonary metastasis by decreasing the activity of CD73. BMC Cancer. 2017;17(1):255.

Ren ZH, Lin CZ, Cao W, Yang R, Lu W, Liu ZQ, et al. CD73 is associated with poor prognosis in HNSCC. Oncotarget. 2016;7(38):61690–702.

Perrot I, Michaud HA, Giraudon-Paoli M, Augier S, Doccquier A, Gros F, et al. Blocking antibodies targeting the CD39/CD73 immunosuppressive pathway unleash immune responses in combination cancer therapies. Cell Rep. 2019;27(8):2411-25 e2419. 

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.